SPRR2A and cancer: Codiak’s exoSTING (engineered exosomes containing small-molecule stimulator of interferon genes (STING) agonist) and exoIL-12 (engineered exosomes containing IL-12) were launched in phase I clinical trials for immune activation in cancer.